Products Affected - Description
Buprenorphine sublingual tablets, Teva
2 mg, 30 count (NDC 00093-5378-56)
8 mg, 30 count (NDC 00093-5379-56)
Reason for the Shortage
- Teva could not provide a reason for the shortage.
- Akorn acquired Hi-Tech Pharmacal in 2014.
Buprenorphine sublingual tablets, Akorn
2 mg, 30 count (NDC 50383-0930-93)
8 mg, 30 count (NDC 50383-0924-93)
Buprenorphine sublingual tablets, Roxane
2 mg, 30 count (NDC 00054-0176-13)
8 mg, 30 count (NDC 00054-0177-13)
Estimated Resupply Dates
- Teva has buprenorphine 2 mg and 8 mg sublingual tablets temporarily unavailable and the company cannot estimate a release date.
- Akorn and Roxane have had product available for several months.
September 17, July 14, April 13, January 23, 2015; December 1 and 22, November 4 and 21, September 11, July 9 and 30, May 5, March 3 and 5, January 8, 2014; December 4, November 5, September 23, August 6, July 2, June 18, 2013, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins